CD8A and colorectal carcinoma: Upon combining stromal LOX‐1 and CD8 status, the CRC patients (n = 128) were divided into four groups, that is, stromal LOX‐1‐H/CD8+ CTL‐H as H/H (n = 30), stromal LOX‐1‐H/CD8+ CTL‐L as H/L (n = 32), stromal LOX‐1‐L/CD8+ CTL‐H as L/H (n = 31), and stromal LOX‐1‐L/CD8+ CTL‐L as L/L (n = 35).